000			01852 a2200469 4500
005			20250513132414.0
264		0	_c19980209
008			199802s 0 0 eng d
022			_a0732-8893
024	7		_a10.1016/s0732-8893(97)81807-x _2doi
040			_aNLM _beng _cNLM
100	1		_aBallow, C H
245	0	0	_aComparative in vitro assessment of sparfloxacin activity and spectrum using results from over 14,000 pathogens isolated at 190 medical centers in the USA. SPAR Study Group. _h[electronic resource]
260			_bDiagnostic microbiology and infectious disease _cNov 1997
300			_a173-86 p. _bdigital
500			_aPublication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
650	0	4	_aAnti-Bacterial Agents _xpharmacology
650	0	4	_aAnti-Infective Agents _xpharmacology
650	0	4	_aBacteremia _xdrug therapy
650	0	4	_aBacteria _xdrug effects
650	0	4	_aDrug Resistance, Microbial
650	0	4	_aEnterobacteriaceae _xdrug effects
650	0	4	_aFluoroquinolones
650	0	4	_aHaemophilus _xdrug effects
650	0	4	_aHumans
650	0	4	_aIn Vitro Techniques
650	0	4	_aKlebsiella _xdrug effects
650	0	4	_aMoraxella catarrhalis _xdrug effects
650	0	4	_aOxacillin _xpharmacology
650	0	4	_aQuinolones _xpharmacology
650	0	4	_aRespiratory Tract Infections _xdrug therapy
650	0	4	_aStaphylococcus aureus _xdrug effects
650	0	4	_aStreptococcus _xdrug effects
650	0	4	_aStreptococcus pneumoniae _xdrug effects
650	0	4	_aUnited States
700	1		_aJones, R N
700	1		_aJohnson, D M
700	1		_aDeinhart, J A
700	1		_aSchentag, J J
773	0		_tDiagnostic microbiology and infectious disease _gvol. 29 _gno. 3 _gp. 173-86
856	4	0	_uhttps://doi.org/10.1016/s0732-8893(97)81807-x _zAvailable from publisher's website
999			_c9371459 _d9371459